We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

By LabMedica International staff writers
Posted on 17 Apr 2025

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease. More...

A significant challenge in manufacturing cell therapy products (CTPs) is ensuring that the cells are free from contamination before being administered to patients. Current sterility testing methods, which rely on microbiological techniques, are time-consuming and can take up to 14 days to detect contamination. This delay poses a risk to critically ill patients who urgently need treatment. Although advanced techniques like rapid microbiological methods (RMMs) can reduce testing time to seven days, they still require complex procedures, such as cell extraction and the use of growth enrichment mediums, and rely heavily on skilled personnel for sample handling, measurement, and analysis. This highlights the need for more efficient methods that provide faster results, meet patient timelines, and involve simple workflows without compromising the quality of the CTPs.

Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP, Singapore), an interdisciplinary research group of Singapore-MIT Alliance for Research and Technology (SMART), along with collaborators have developed an innovative solution to quickly and automatically detect microbial contamination in CTPs during the manufacturing process. By measuring the ultraviolet (UV) light absorbance of cell culture fluids and employing machine learning to identify light absorption patterns indicative of microbial contamination, this novel testing method aims to reduce sterility testing time, enabling quicker availability of CTP doses for patients. This is especially critical in cases where timely administration of treatments could be life-saving for terminally ill patients.

In a study published in Scientific Reports, the SMART CAMP team explained how they integrated UV absorbance spectroscopy with machine learning to create a method for label-free, non-invasive, and real-time detection of cell contamination in the early stages of CTP production. This new approach has several advantages over traditional sterility tests and RMMs. It eliminates the need for cell staining to identify labeled organisms, thus making the process label-free. Additionally, it bypasses the invasive procedure of cell extraction and provides results in less than 30 minutes. The method offers a quick "yes/no" assessment of contamination, enabling automation of cell culture sampling with a streamlined workflow that requires no extra incubation, growth enrichment mediums, or extensive manpower. Furthermore, the system does not need specialized equipment, making it a cost-effective solution.

“Traditionally, cell therapy manufacturing is labor intensive and subject to operator variability,” said Prof Rajeev Ram, Principal Investigator at SMART CAMP, MIT Professor, and corresponding author of the paper. “By introducing automation and machine learning, we hope to streamline cell therapy manufacturing and reduce the risk of contamination. Specifically, our method supports automated cell culture sampling at designated intervals to check for contamination, which reduces manual tasks such as sample extraction, measurement, and analysis. This enables cell cultures to be monitored continuously and contamination to be detected at early stages.”

Related Links:
CAMP


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.